Patent SG-11201806150R-A (SG)
Title: Psma and cd3 bispecific t cell engaging antibody constructs
Inventor: RAUM TOBIAS
IPC: C07K16/30
Filed: 2017-02-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/134158 Al 10 August 2017 (10.08.2017) WIPO I PCT 11111111111111 0 111011111111111 010 11111 01110111 011111111 0111H110 111111111 0111111 (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/30 (2006.01) (21) International Application Number: PCT/EP2017/052239 (22) International Filing Date: 2 February 2017 (02.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/290,875 3 February 2016 (03.02.2016) US (71) Applicant: AMGEN RESEARCH (MUNICH) GMBH [DE/DE]; Staffelseestrasse 2, 81477 Munich (DE). (72) Inventors: RAUM, Tobias; c/o Amgen Research (Mu- nich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). MUENZ, Markus; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BROZY, Jo- hannes; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). KUFER, Peter; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). HOFFMANN, Patrick; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Mu- nich (DE). FRIEDRICH, Matthias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). RATTEL, Benno; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BOGNER, Pamela; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). WOLF, Andreas; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). POMPE, Cornelius; c/o Amgen Re- search (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). (74) Agents: WEINZIERL, Gerhard et al.; Schiweck Weinzi- erl Koch, Landsberger Strasse 98, 80339 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) W O 20 17 / 13 415 8 Al (54) Title: PSMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS (57) : The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3 E chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.